The development of selective agents that eliminate senescent cells (senolytics) and SASP-modulating agents (senostatics) could therefore potentiate the anti-tumor effects of senescence driven by PTEN-loss in fibroblasts by reducing the pro-tumorigenic effects associated with the upregulation of SASP [393]. The gene discussed is PTEN; the disease is neoplasm.